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cording to the AHA/ACC Guidelines was appropriately pedormed in 8g (88%) 
of the patients, Including 19 (18%) patients who underwent nuclear stress 
testing and g (9%) eehocardlogrsma, Overall pariopaMtlve compllcstions 
weM; 7 (7%) CHF, 6 (6%) atrial fibrillation, g (g%) ioohemla or MI and 2 (2%) 
deaths, Length of stay was 8,2 :t: SD 0 days, Among the lg patients that 
underwent nuclear atMss testing ,5 (26%) developed podopoMtlvely CHF, MI, 
or Ischemla, The 12 (12%) patients who did not receive further preoperative 
tcsttng when Indicated did not develop higher parioperstlve complications 
than the rest of the cohort, 
No dlffaMnoe was found on Individual or eomblned po~toporstlve corn. 
pllcatlona nor In length of stay among the phyalol~n gMups pedormtng the 
preol~Mtlve valuation, 
Conclusion" The Maults Indtoste that the ACOtAHA Preoperative Cardlo. 
vneular Guidelines aM I~rgely being followed at this hospital and that further 
non.lnvsmlve testing did not lower the periopeMtlva events in this cohort, 
• Prognoatlo Risk Stratlfl©atlon With 8PECT 
Imaging: Results From a 20,340 Patient 
Multlcenter Registry 
D,S, Barman, R, Haohamovltoh, L Shaw, H,C, Lawin, A,E, lakandnan, 
1", Betoman, ~rs .S fne i  ~nel ~.Ctly C~t I~ O~tcomes R~s¢,arch 
F~ur~l~l~Qn, LA, CA, USA 
B~c/(gMund: Effective cllntoeri decision making st[nod st ri~k reduction re. 
qUIMS use of eCOUMto nonlnvaslve tests that are able to strattlv patients (pts) 
es to their rate of important oardlso outcomes, 
Methods: 20,340 pts undergoing SPECT waM prospectively enrolled 
from 3 institutions (follow..p ,~ 1.8 ~ t years), SPECT summed stress score 
(SSS) was dedved from a 20-segment model incorpoMtlng seventy/extent of
partuslon deMcts: 60% ,~ dual.Isotope, 40% - TI-201, 0,7% =, exercise, 33% 
- phafmacologlo StMSS imaging, Pooled data were compared tot outcome 
dtfferoe~,'ma using a Mndom effects modal correcting for internal validity with 
S corrs¢ted (2-aided) ,x .° test, 
Re .~:  Pts WeM on average =, 63 yrs, 33% female, Annual cardiac death 
(CO) mt~a =~ 1,1%, myocardial Infarction (MI) ~ 1,2%, Event rates by SSS: 
Ann,a~me~/Rafe~ (% p~} Cardiac Death k~/oca~hal Infarction 
5~ 0-,.I (41%) 0,~% 0,4% 
55 4-,,8 (1P.~) 0,8% 1 5% 
SS 9,,-iS (12%) 10% t 2"° 
S$ ~ t 3 (30%t 25%" 22%' 
"p • 0,0001, 
The annualtzod relative nsk of CD and CD or MI was 4,8 (95% CI = 
3,6--6,3) and 3,7 (95% CI = 3,1-4,5)-fold higher for pts with SSS . 13, There 
was an 84% (95% CI = 75-90) and 82% (95% CI = 76-84) lower ask of CD 
and CD or Mt in pts with SSS = 0-3. 
Conclusion: Clinical doctston making aimed at ask reduction employing 
medical and surgical Interventions may be enhanced by the identification of 
cardiac risk on nuclear SPECT imaging, 
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11160-1291 Increased Incidence of Adverse Events in 
Follow-up of Patients Not Previously 
Revescularlzed but who Have Abnormal SPECT 
Thallium Studies 
W.A. VanDecker, P,M. McNelis, J, Kaspar, A. Iskandrian. Allegheny 
University of the Health Sciences, Philadelphia. PA, USA 
Backgn~md. The excellent prognosis associated with a normal scintigraphy 
study ;s well documented. In an era of outcomes management, it is impor- 
tant to understand the implications of abnormal stress scintigrsphy so the 
aggressiveness of management plans can be tailored appropriately, 
Methods: We Identified 209 patients in our database with abnormal 
SPECT thalliums IMm 6/94-6/96 and made follow-up phone inquiries about 
health status. The study population included 127 males, 82 females; age 
66 ± 11; 153 hypertensives, 70 diabetics, 12 with history of myocardial in- 
farction, of whom 84 exercised and 125 underwent pharmacologic stress. 
Mean follow-up was approximately 17 months, Study patients were identi- 
fled with no history of previous coronary artery bypass grafting or balloon 
angloplasty and with no myocardial infarction within 2 months Rtudies were 
sco:ed abnormal with more than mild dufects in 2 segments. 
Results: During a mean follow-up of 17 months, there were 26 cardiac 
deaths (12%), 10 non-fatal myocardial infarctions (5%) and 52 (25%) com- 
nan/rovascularizations. The annual hard event rate (death or infarction) wa~ 
12%/year. 
Conclusions: Abnormal SPECT images in a previously non-rovascular- 
ized population are associated with a high incidence of hard cardiac events 
and are frequently utilized in subsequent revascularization decision making 
1160-1301 Value of Quantitative Stress Prognostic 
i 
Myocardial SPECT Imaging In Patients With 
Unstable Angina 
W,S, Hweng, A, J~Gir, H,A, Daklk, Z,-X, He, E, CwaJg I , J,J, Mahmanon, 
M,$, Versnl, Bay/or College of Medicine, Houston, TX, USA: ~ Sponsomcl by 
CAPES, Brazil 
Recent guidelines have recommended nonlnvemlve risk afMtification o1 ~-  
looted patients with unstable angina, However, them aM scanty data on 
the pMgnos(10 slgnlfloeooe o! quantitative atMaa myocardial peffusmn to. 
mogMphy (SPECT) In this patient population, We studied 137 ¢on8~ 
patients admitted with a ctinloal diagnosis el unstable angina who uedemmnl 
quantitative stress SPECT bel0M hospital discbeege, 
During a mean follow.up el 27 ± 19 months, 22 patients (16%) sustained 
a hard cardioo event: sardine death (n =, 15) end non.tarsi MyOCactkal in. 
rotation (n ,= 7), By univerista nalysis, predictors of subsequent hard events 
included a history of congestive heawl failuM (p; 0,006), an abeormat SPECT 
study (p =~ 0,03t), the number of abnormal vaScular tomtones on SPECT (p = 
0,013), perft~ion detect site ~ 15% (p = 0 ,~)  and a !elf vent~lar 
tMction ~fi0% (p '= 0,052), Peduslon defect site was signihcanity larger in 
patients with events than in t~e without events (21 :L 18% vs 11 :t 14%, 
p = 0,035), Age, gender, hypertension, prior history el myocardial infarotion, 
number of comnsny vessels with ~50% stenosis or Mvasculanzatmn ~1.  
ity WeM net significantly essoctteted with subsequent events. Muflwanate 
COX regMssian analysis identified 2 variables as independent ~edictm's o! 
prognosis', percent detect size ~ 15% (p = 0.0027) and diabetes mellitus (p = 
0,O3), 
In conclusion, quantitative SPF.CT prov~ea independent I~ognosec in. 
fore, alien in patients with unstable angina pectons. 
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11161 - 1491 Comparative Effects of Straptoklnase and 
Llposome~ancapsulatsd Streptoklnase on 
Platslet Aggregation in Vitro 
WL Daisy, O.E Lapstey, A.S. Janefl. West Roxbuqf VA Medmal Center and 
Harvard Medcal School, Boston, MA: The Liposome Company. Pnnce~'l. 
N J, USA 
Background: Stroptokinase (SK) Is an effective agent in reducing morbtcl~ty 
and mortality from acute myocardial infarction (MI) Since SK =s a bacte- 
nat-denved protein, exposure to SK generally induces production ot specific 
antibodies, some of which are capable of initiating platetet aggregation. The 
presence of these antibodies may limit the effectiveness of the drug and is 
rasponsibte lor the prohibition against retreating patients with SK after an im- 
tial exposure. Many experimental pproaches have been made in an attempt 
to improve the pharmacologic and immunologic profile of SK. Recent reports 
have described the enhanced thrombolytic potency of liposome-encapsu- 
Isled SK (Lipe-SK) in animal models ot acute thrombosis when compared to 
standard SK. 
Methods: In this study, we compared equivalent doses of SK and Lipo-SK 
for their capacity to induce platelet aggregation m vitro. These experiments 
were performed using platetet-nch plasma from fourteen individuals who had 
previously been treated with 1.5 million units of SK lor acute myocardial 
infarction. 
Results: SK in a dose of 5,000 u/ml induced platetet aggregation in 12 
of 14 patient samples tested. In contrast, Lipa-SK laded to =nit=ate platelot 
aggregation in any of the samples (p .- 0.0001 ). 
Co. Jusiot,. These data suggest that the packaging of stroptokinase into 
liposome provides a vehicle for delivenng drug that has retained throm- 
bolytic properties while at the same time reduces the immunologicaliy-based 
undesirable properties of the agent. 
1161 - ;50 ] Mechanical Thrombectomy Using the Anglo|et 
= 
Catheter in the Treatment of Acute Myocardial 
Infarction 
J.A, Silva, S.R. Remus, R. Kuntz, K. Dandreo, J. Popma. For the VEGAS / 
and VEGAS II/nvestigalors: New Orleans, LA, USA 
We studied the clinical and angiographic outcome ot 89 pts with acute 
myocardial infarction (MI) treated with the Angiojet in a multicenter t.al. All 
pts were treated within 24 hours of the clinical onset of MI. Mean age was 
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59 ~ 11 years (69% mates). History of prevmus MI was present in 4b% el 
the I:)ts and 13% presented with cardtogenic shock, The culpnt lesion was 
located in tha LAD (23%), RCA (37%), LCX (11%) or a ~apbenous vein graft 
(28%), Adjunhv~ pereutaneou~ mvasculanzation wag I~rtormed tn 93% of 
the I~t~ents; PTCA alone (46%), coronary stentmg (46%), and rotational 
athemctomy (1%) Pemont dmmeter stenosm was reduced from 82% to 50% 
after Anglolet. and to 2_4% after (f~finitM~ treatment (P = 0,0001 ), 
Procedural SuccesS. defined as the esto~ti0n of TIMI 3 flow and m. 
hO~l~l ~ froth (~41th, eff~flf]6ftf bY~ISS §urg~ry or malor d~saJ~ling 
~tf¢~ke, wSS ~i~hed in g8%, Procedure compl~tmns included d~st~l 
~ lza l lon  (2%), translenl no.relfow (2%), and al~'upt Closure ( :~)  At 1 
Oir,¢al !~ UP, 2 (2%) pl~ cf;ed; 3 (3%) patients had recurrent Mt 
and 2_ (~'~) requtft~l mpe-~h~;I t~lOel vessel parcutaneous re~a~lanzation 
At ! month fcdlOw UP 82 (92%) pabents were stive and free from recurrent MI 
and repeat mvasO~anzaben pmOadum, 
Conctuszons: The Ar~,olet m a promising adtuntrve device for establishm 9
pateno/m t h ~  laden Les~.  !t t5 Of parlv~ula f utility if1 ~cute mvo¢ardlal 
mfarcl~n where the ~nce  Of coronary t~rom~ enhances the pa~prOco, 
dum C~tm~ rate. 
• !. Ipolomal POE-! Adjun~ive Treatment for 
Acute Myo¢a~ia l  In fa~l lon:  Final Resul ls  of  the 
UFT Pifot Trial 
RW, Srsalhng, R P Ka~rg .  R Wemer. DG Ebemote. U Thadam, 
E Bates, G.B Hal~b, D. ~k~hterno, YC Park J J Fre~ag For the LIFT 
~t~ja~rs ,  The Urm~=m;t), of Texas Med~'al ~ 1  and Hermann 
~ Ho~tOn. T~a.~ USA 
Backg~otmd ~ PGE-1 (TLC-C53) mhd~ted platelets and tCAM-1 
expmssmn which accelerated ~ombolysLS and reduced infarct size m an,real 
myocardial infambon models. 
A~thods: To evahJate the effect of TLC-C53. an mvest~ational drug, on 
mroml~ and infarct saNage, 121 pat~,nts wdh myocardial Infarction (MI) 
were random~ed to ~ edher TLC-C.53 (bohn, plus 5 add~onal closest48 
hours) or' idacebo lust prior tO trot'if-loaded t-PA Coronary ~ was 
performed at 30, 60 and 90 mmufes and 5-7 days after admission. Leh 
ventncuk~ was pertom'ted acutely and 5-7 days po~ Mr. Ang;ograms 
were analyzed for TIMI flow. oJo4~l and ~ I  left ventncutar func~an 
Resu~s: Patents were well matched for age. weh~ and time to treatntent 
There was a trend toward better eady T1MI 3 patency in the TLC.C53 patients 
at 60 minutes post treatment (53 vs 47%. p = N$) However. at 90 n',nutes 
the T1MI 3 patency was equwa~ent (54 vs 55%). There was also a trer~l 
toward lower remtamtmn and re-oo:lus~n rn the TLC-C53 group compared 
to placebo (2 v5 11% respeclwely; p = 006) There were no ~ferences =n 
acute or folfow-up ejection fractmn or regional km.c~on between the groups 
Conctus~" TLC-C53 chd not produce drama~c ~mprovements m ~nfarcl 
sah~age o~ vessel patency at the dosage level and frequency evaluated 
however ~t may reduce recurrent tschen.a and re~ntaret~on 
I 116%152t  Phase I Safety Trial of Soluble Complement  
Receptor Type I (TP 10) in Acute Myocardial  
Infarct ion 
GJ. Pe~ry. PR  E|senberg. J L  Zimmerman. J Lewn Bfrrnmgham Veterans 
AcMu.'~strat;o.'~ Medical Center. Bzrm~ngt~m AL. T Cell Soences. Needham. 
MA. USA 
Background: Complement actwatmn occurs v~ acute MI and may contnbute to 
ropeduslon in|u~. Thus complement inhtb~bon m~ght reduce mlury tollowng 
PTCA or thrombolysts for MI. Th~s phase I trial tested the pharmacok~netics 
(PK) and safety ot the complement inhibitor TP t O (1" Ceil Sc~encos, Needham. 
MA). a recombinant soluble form of human e~'th=ocyte complement receptor 
1 
Methods: TP10 was given by open label, ascending dose schedule (01, 
0.3. 1.3. or 10 mg/kg Lv. over 30 rain.) to 24 patrents re:eiwng lytics (n = 9) 
or pnma~y PTCA (n = 15) for first MI. CHS0, C3a, and C4a were measured 
at 0. 8, 24.48. and 168 hr. 
Results: There were no immunogemc responses or senous adverse ef- 
fects directly attnbuted to TP10. Non-compartmental PK analysis showed 
TP10 h,~ = 94.5 ± 57.5 hr. TPtO caused dose (p • 0.05 for 0.1 vs higher 
doses) and time-dependent (p < 0.(}5 for 8 and 24 hr vs O and 168 hr) de- 
crease o! CH50 (2 way ANOVA). C3a tended to fall at 8 h relative to 0 h (p 
= ns] at all TP10 doses, in contrast to the predicted nse with MI. suggesting 
complement inhibition. As expected based on the mechanism of action of 
TP10, there was no time or dose effect on C4a. In patients receiving lyrics 
there was a trend toward lower CKMB (normalized to ECG area at risk) in 
those receiving higher ( > 1.0 mg/kg) vs lower dose TP10 (52 vs 511. p = 0.06). 
Conclusion: TP10 is well tolerated and non-immunogenic in ML The 
expected rise in C3a during MI was not seen at any dose of TP 10. suggesting 
effective complement suppression in these patients. 
I 1161-1 53 } A K*-ATP Channel Opener. Nl¢ofandl;. Bruited 
Imar¢t Size In Psttents With A=ut~ Myo¢a~llal 
InMrcflon 
Y Sakata. K. Kodama, A. Hitayama. M. Kitaka~.."e, M. Hoe. O~aka PeAce 
HOs~al, Osaka; ~ U ~ ,  S~4a, JN~O 
Background: We have moe~t~t repotted tt~t ft~Oflff~l (NCR), a K'.ATP 
channel ol~ner , restori~ blood flow tO ~ ~ myocard~um patlem~ 
(pt~) wllll acuto myoc~rd~! Infafcllon (AMI), ~ , i t  ~ ur4mown 
the mf~r~t s~'e,ltmfling effe~-I of NCR, Thus we SOg~ tO ~wel~ate 
NCR tirol infarct s~ in I~  ~ th~f fI~!t Nl~mof AML 
Me~O~: Alter {zu¢~sful comnap/inflow, !S !~ ~ ~ W  
ad~,mstmhen of NCfl (2 rag), and 18 pts moeNed plar..eoo, Pe~ mm~n 
c~atlne ktn.~-e (CK) levels, defect vek~me m(l~w (DvI) O~em,ned by ma~ 
hum.,~01 ~,PECT, g ro~ ~ ~ (E~ aed left ~mt~ 
foim volume inde~ (EDVI) in the ~uto stage and one_ month a f t '  the 
were congsamd between the two ~ o1 patmm1~, 
Resu,ls: !) Thee were no differef~es between the two gmupa m age, 
gender and t~me to repartus~,n (4.2 ~: 2`2 VS 4.6 ± 1,6 hm, p = O.e4). 2) Peak 
CK (2248 ± 1386 vs 3642 ~ 1624 U/L p = 0.03) and peak CK-MB (191 ± 
119 VS 303 ± 122 U/L, P = 0.03) leve~s'~i~e s~mflcanfty lower m NCR group. 
3) DVI was s~gnd]cantly lower in NCR group (961 ± 735 v~ 1557 ± 781 U, 
p = 005) 4) EF was s~t~, i ;y  m~pmved m a month In NCR group (42 ± 
14 to 52 ± 16%. p = 0.03), while ~I was not m placebo group (44 ± 11 1047 
13%, p = 026). 5) EDVI d~d not differ bolh at the a~de stage and a month 
alter the onset. 
~ :  fotraco~na~/~.qmi,aiK:m of NCR limd~l inMrct size and 
• nlp¢oved flmclional ~ in a m~nl~ aftra, the onlof. T h u s ~  
nv:orancbt aa~n~stra~ seems to be a useful adiunctn~ therapy follow~g 
~uccess~Jt coronary repertusmn m patmnts w~th AMI. 
Diagnost ic  Methods of ~ i n g  Ischemia 
Wednesday, April 1, 1998, 9;O0 a .m.-11:00 a,m, 
Georg ia  Wor ld  Congress Center,  West  Exhibit Hall Level  
P resentat ion  Hour:. 10:00 a .m. -11 :00  a.m. 
I 1162-131J  Beneficial Effects of  Tmglitazone in Vuospast i¢  
Angina Peetods With Diabetes Mellitus 
T Murakams, Y AmL B. Kaku. Fukui CaK1mvascular Center, Fukua, Japan 
BackgrounO~: The retahonshlps between msuhn resistance and coronary 
affe~ ( ~  have a great deal of affentmn. 
P .~:  In order to investigate wheffmr t~gfrtazone, recently used for m~ 
suitn resistance, has t rac ts  upon clinical manlt'eslations of corenary a f t i~  
~.ease we adm~mstered troglffazone for tour months in diabetic patients 
wm~ ar~ographlcally decumenmd co~nary vasospasm and resm~ual ngina 
pec~or~ even ~ commnl~al me~lK)ns for vasospaztic angina peclons 
(n = 8) At base,me and at four months after medica l ,  we assessed a~gt- 
nal e ~  and non.~nvas~,ely measured the macth~e changes m lumen 
diameter of right brachlal artery folfowmg transient ocdu~uon four five mmutos 
(FMD; flow-nle~ated @hum-dep~- ,G~sl  vasodilatlon), and affe¢ sublm. 
gual admlmstra~on of (300 .g) glycenl tnnrlrate (GTN; endotbelium-ind~.~- 
dent vasod~latren). 
ResuRs: Dur;,tmn of anginal epmodes (AP; minutes per month) were 
s~T,f¢an~ redt~-ed after med¢atren. FMD was improved after medtcatmn, 
GTN was sit.tar oefore and after meo~cahon Reductmn of AP was coffelMed 
to rn~rovement of FMD (r = 06. p < 001). 
groined;cat,on poslmeOtc-af~on p valuo 
AP 72 :. 68 14 ~- 17 004 
FMD 43~ 14% 66= 16% 003 
GTN 11 5 ~43% 133 ~: 29% ns 
Conctusrons: These findings suggest that lroglitazone improves endothe- 
hum-dependent vasomactw'~ms and reduces anginal episodes in diabetic 
patients w~th vasos~asbc angina pecfons, and insulin-resistance may con. 
tnbute to clinical manifestation el vasospashc angina pacfons wdh diabetes 
meltitus. 
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